Cannformatics
Cannformatics is a privately held US biotechnology company developing a saliva-based Cannabis-Responsive™ (C-Res™) biomarker platform with AI/machine-learning bioinformatics to personalize medical cannabis treatment. Pre-revenue, it serves healthcare providers and patients, initially focused on autism and expanding into dementia and migraine.
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Cannformatics does
Cannformatics, Inc. is a privately held US medical cannabis biotechnology company developing a proprietary saliva-based Cannabis-Responsive™ (C-Res™) biomarker platform combined with an AI/machine-learning bioinformatics engine to personalize medical cannabis treatment. The core technology applies metabolomics and lipidomics to pre- and post-consumption saliva samples to identify metabolites that shift toward physiological norms in response to cannabinoids, then uses those Cannabis-Responsive biomarkers to match individuals to optimal cannabis products, dosages, and consumption methods. The company was formally established circa 2020 (consistent with its website copyright and Privacy Policy effective date of 05/19/2020) and is headquartered in San Francisco, California, though firmographic data lists a 2017 founding year that may reflect earlier pre-incorporation work.
Cannformatics is currently pre-revenue and operates as a clinical-research-stage biotechnology firm. Its commercial roadmap envisions a saliva-based lab testing service marketed initially to healthcare providers (HCPs) and, eventually, direct to consumers, with revenue likely structured as per-test or subscription laboratory fees and complemented by an enterprise bioinformatics/insights offering for clinicians. The initial clinical focus is autism spectrum disorder (ASD), with active expansion into dementia via a proof-of-concept study with Northwell Health and into migraine via a planned joint venture with Dr. Laszlo Mechtler and the DENT Neurologic Institute that intends to enroll 150 migraine patients beginning in the second half of 2026 after IRB approval. Stated future indications include anxiety, pain, neurodegenerative diseases, and chemotherapy-induced nausea/vomiting.
The company is led by a small executive team — CEO Itzhak Kurek PhD, CCO Kenneth Epstein, VP Computational Biology Mike Siani-Rose, and CTO/CLO Robert McKee — supported by a high-profile advisory board including former US Congressman Edward Feighan, UCSF oncologist Donald Abrams MD, pediatric cannabis physician Bonni Goldstein MD, and Emmy-winning media personality Montel Williams. Cannformatics has published four peer-reviewed papers across Nature's Scientific Reports, Cannabis and Cannabinoid Research, Journal of Neurology & Neuromedicine, and Journal of Anesthesia & Analgesia; holds registered trademarks on Cannabis-Responsive™/C-Res™/C-ReB™; and self-attests HIPAA, GDPR, CCPA, and COPPA compliance. With only ~$100K in disclosed funding and 1–10 employees, the company is highly capital-constrained relative to the scale of its clinical and commercial ambitions.
Cannformatics firmographics
Firmographics- Name
- Cannformatics
- Legal name
- Cannformatics, Inc.
- Website
- https://cannformatics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cannformatics is a privately held US biotechnology company developing a saliva-based Cannabis-Responsive™ (C-Res™) biomarker platform with AI/machine-learning bioinformatics to personalize medical cannabis treatment. Pre-revenue, it serves healthcare providers and patients, initially focused on autism and expanding into dementia and migraine.
- Ownership category
- akta.pro rank
Cannformatics industry classification
Industry- Product category
- Cannabis Biotechnology / Medical Cannabis Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Cannformatics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cannformatics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pre-revenue / R&D stage with planned lab service launch: Currently a research- and clinical-study-stage biotechnology company; not yet generating commercial revenue. Announced intent to launch a saliva-based lab testing service for personalized medical cannabis treatment in migraine and other conditions (joint venture with Dr. Laszlo Mechtler, expected post-IRB approval in 2H 2026).
- Future saliva-sample testing service to consumers/HCPs: Planned future service where individuals send a baseline saliva sample, receive product/dosage/consumption-method recommendations, retest post-consumption, and receive continued refinement. Implies a per-test or subscription-style laboratory service revenue model once launched.
- Potential HCP data/biomarker insights offering: Stated intent to provide healthcare providers with a bioinformatics platform that helps them understand the impact of medical cannabis treatment on each individual patient — implying potential enterprise data/insights revenue alongside the lab service.
Go-to-market motion4 records
Distribution channels3 records
Marketing channels7 records
Cannformatics product offering
Product offeringCore offering
Cannformatics is a biotechnology company that has developed a proprietary saliva-based Cannabis-Responsive™ (C-Res™) biomarker platform combining metabolomics, lipidomics, and AI/machine-learning bioinformatics to objectively measure how each individual responds to medical cannabis and recommend an optimal product, dosage, and consumption method. The company currently delivers this technology through IRB-approved clinical research collaborations with healthcare providers and academic medical centers (e.g., Northwell Health, DENT Neurologic Institute), with a planned future saliva-based laboratory testing service for both consumers and HCPs.
Product overview
Cannformatics offers a single integrated biotechnology platform centered on its proprietary Cannabis-Responsive™ (C-Res™) biomarker technology, supported by an AI-driven bioinformatics platform. The C-Res biomarker technology is the core scientific engine: a saliva-based metabolomics and lipidomics assay that identifies metabolites changing in response to cannabinoids. The AI-driven bioinformatics platform layers on top to match each individual with the best product, dosage, and consumption method using the C-Res biomarker database and machine learning models. Application of the platform is delivered through a portfolio of clinical research programs — the Children with Autism (ASD) Pilot Study, the Dementia Study (with Northwell Health), and the Migraine Clinical Study (with Dr. Laszlo Mechtler / DENT Neurologic Institute) — each serving as a vertical-specific validation of the underlying C-Res platform. Supporting research publications include the ASD Study White Paper, which consolidates findings from the platform's three peer-reviewed papers.
Differentiator
Problem solved
Functional benefit
Brands
- Cannabis-Responsive™ (C-Res™): Cannformatics' proprietary biomarker technology and bioinformatics platform for personalizing medical cannabis treatment.
Products and services
- Cannabis-Responsive™ (C-Res™) Biomarker Technology Cannformatics' core proprietary saliva-based metabolomics and lipidomics testing platform that identifies Cannabis-Responsive (C-Res) biomarkers — metabolites that change value in response to at least one cannabinoid — by analyzing PRE vs PEAK saliva samples and comparing them against a typically developing physiological range (≥70% participant consistency rule). It produces objective, quantitative pharmacometabolomics data about how an individual responds to medical cannabis, in a format analogous to traditional blood/urine diagnostics, for use by healthcare providers and researchers.
- AI-Driven Bioinformatics Platform Bioinformatics platform layered on top of the C-Res Biomarker Technology that uses the Cannformatics biomarker database and machine learning models to match each individual with the best-fit available medical cannabis product, dosage, and consumption method, and to refine recommendations over time as new saliva retest data and product information become available. Demonstrated in peer-reviewed research (Nature's Scientific Reports, August 2023) and intended for eventual deployment to consumers and healthcare providers.
- Saliva-Based Personalized Cannabis Lab Testing Service (Migraine Joint Venture with Dr. Laszlo Mechtler / DENT Neurologic Institute) Planned saliva-based laboratory testing service for personalized medical cannabis treatment in migraine and other neurological conditions, announced as a joint venture with Dr. Laszlo Mechtler (DENT Neurologic Institute, whose cannabis clinic has treated 15,000+ patients). The service will use the C-Res biomarker technology and AI-driven bioinformatics platform to provide patients and HCPs with objective, individualized product, dosage, and consumption-method recommendations; intended to enroll 150 migraine patients in the supporting observational study.
Quantifiable outcome
- Identified 65 potential Cannabis-Responsive biomarkers from ASD pilot study
- +4 more outcomes
Companies that use Cannformatics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Cannformatics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature6 records
Cannformatics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship and core.
- Dr. Laszlo Mechtler / DENT Neurologic InstituteflagshipCannformatics and Dr. Laszlo Mechtler announced intent to launch a joint venture developing a saliva-based lab testing platform for personalized medical cannabis in migraine and other neurological conditions. Dr. Mechtler is president of DENT Neurologic Institute and leads its cannabis clinic (15,000+ patients treated). The study plans to enroll 150 migraine patients and is expected to begin in the second half of 2026 after IRB approval.
- Northwell HealthflagshipCannformatics and Northwell Health, New York State's largest healthcare provider, are collaborating on a proof-of-concept dementia study applying the C-Res biomarker platform to patients with behavioral and psychological symptoms of dementia (BPSD). The study received IRB approval and is commencing patient recruitment, announced at the 2nd Annual New York State Medical Cannabis Symposium.
- CannabotechcoreFirst clinical study using Cannabis-Responsive biomarkers to evaluate the impact of Cannabotech's "MycoCann NeuroPain" product in managing chronic neuropathic pain. Announced as a joint research collaboration.
- Bonni Goldstein, MDcorePress release: "Cannformatics Strengthens Its Advisory Board with Appointment of Medical Cannabis Expert and Physician Bonni Goldstein, M.D." Formalized her role as a clinical advisor.
- Honorable Edward Feighan (former U.S. Congressman)corePress release: "Former U.S. Congressman Edward Feighan Joins Cannformatics Advisory Board" as Business & Policy Advisor and Executive Chairman of Vitality Bio, adding regulatory/policy expertise.
- CanniatriccoreOne of three "pioneers in using medical cannabis for treating autism spectrum disorder" that came together to sponsor Cannformatics' ASD Pilot Study. Featured as a sponsor on Cannformatics' ASD pages and listed as a sponsor organization.
- WPA4A (Wholistic Pediatrics and Adult Autism)coreCommunity/sponsor partner for Cannformatics' ASD Pilot Study. Listed alongside Canniatric as a "valued sponsor" on the ASD study page, supporting recruitment and community engagement for pediatric autism research.
- Bonni Goldstein, MD / Canna-Centers Wellness & EducationcoreClinical Advisor to Cannformatics and sponsor of the ASD Pilot Study; owner and Medical Director of Canna-Centers Wellness & Education. Instrumental in study design and recruitment, including suggesting ASD as Cannformatics' first indication based on her pediatric practice.
- Kenneth R. Weinberg, M.D. / Cannabis Doctors of NYcoreStudy Co-Investigator & Advisor for the Dementia Clinical Study. Serves as Clinical Advisor for Alzheimer's disease and is associated with Cannabis Doctors of NY.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Cannformatics competitors and assessment
Company assessmentDirect peers
- Emerald Scientific: Cannabis testing supplies and services provider, including The Emerald Conference. Comparable to Cannformatics as a science-focused enabler of cannabis laboratory analytics and research.
- Cannabotech: Clinical-stage cannabis biotechnology company developing cannabinoid-based therapeutics. Cannformatics' existing co-development partner (MycoCann NeuroPain study for chronic neuropathic pain), making it both a peer and a partner in the cannabis biotech space.
- Steep Hill Labs: Cannabis testing and analytics company offering laboratory-grade analytical services to the cannabis industry. Comparable to Cannformatics as a science-driven cannabis diagnostics and analytics platform, though focused on product/cultivar testing rather than patient personalization.
- Anresco Laboratories: Cannabis and food testing laboratory providing analytical chemistry, microbiology, and regulatory compliance testing for cannabis products. Overlaps with Cannformatics in bringing laboratory science to the cannabis value chain.
- Confidence Analytics: Washington-state licensed cannabis testing laboratory offering analytical services for potency, contaminants, and terpenes. Comparable as a third-party cannabis testing and analytics provider serving the regulated cannabis industry.
Broad incumbents
- Jazz Pharmaceuticals: Acquired GW Pharmaceuticals in 2021, making it the owner of Epidiolex (cannabidiol) and the leading pharmaceutical incumbent in FDA-approved cannabinoid therapeutics. Comparable as a broad biopharmaceutical incumbent with serious commercial cannabis therapeutic assets.
- Tilray Brands: One of the largest global cannabis operators with pharmaceutical, consumer, and medical cannabis business lines. Represents the broad incumbent in medical cannabis that Cannformatics' biomarker platform could ultimately serve or be acquired by.
Emerging players
- Zelira Therapeutics: Clinical-stage cannabinoid therapeutics company with multiple indications including ASD, insomnia, and chronic pain. Comparable as a smaller, indication-focused cannabis biotech pursuing clinical validation in similar therapeutic areas.
- Canna-Centers Wellness & Education: Bonni Goldstein MD's medical cannabis practice and a Cannformatics advisory board partner. Comparable as a clinical medical cannabis practice serving pediatric and adult patients with complex conditions, and a potential distribution channel for Cannformatics' future lab service.
- Zynerba Pharmaceuticals: Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for rare and near-rare neurological and psychiatric disorders, including ASD and Fragile X syndrome. Directly comparable in targeting cannabinoid-based treatments for pediatric ASD.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Cannformatics social profiles
Digital presenceCannformatics compliance and trust
Trust signalCompliance5 records
Cannformatics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cannformatics leadership team
Management profileNumber of profiles
Profiles4 records
Cannformatics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cannformatics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cannformatics
What does Cannformatics do?
Cannformatics is a biotechnology company that has developed a proprietary saliva-based Cannabis-Responsive™ (C-Res™) biomarker platform combining metabolomics, lipidomics, and AI/machine-learning bioinformatics to objectively measure how each individual responds to medical cannabis and recommend an optimal product, dosage, and consumption method. The company currently delivers this technology through IRB-approved clinical research collaborations with healthcare providers and academic medical centers (e.g., Northwell Health, DENT Neurologic Institute), with a planned future saliva-based laboratory testing service for both consumers and HCPs.
Is Cannformatics a public or private company?
Cannformatics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cannformatics founded?
Cannformatics was founded in 2020. It employs 1 to 10 people.
Where is Cannformatics based?
Cannformatics is headquartered in San Francisco, United States, in the North America region.
How does Cannformatics make money?
Three revenue lines are on record. Pre-revenue / R&D stage with planned lab service launch is the primary driver. The others are future saliva-sample testing service to consumers/HCPs and potential HCP data/biomarker insights offering.
Who are Cannformatics's main competitors?
Direct peers on record are Emerald Scientific, Cannabotech, Steep Hill Labs, Anresco Laboratories and Confidence Analytics. Broad incumbents are Jazz Pharmaceuticals and Tilray Brands. Emerging players are Zelira Therapeutics, Canna-Centers Wellness & Education and Zynerba Pharmaceuticals.
Does Cannformatics have an API?
No public API is recorded for Cannformatics.
What industry is Cannformatics in?
Cannformatics's product category is Cannabis Biotechnology / Medical Cannabis Diagnostics. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714.